Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANTA: Vistusertib vs Everolimus with Fulvestrant in Breast Cancer
NCT02216786Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Jan 2014
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of vistusertib in breast cancer (4 arms), sponsored by Queen Mary University of London. Primary endpoint: Progression-free survival at 100 weeks. Started Jan 2014; status: completed.
02
Drugs
vistusertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02216786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216786.